Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jonathan Perera"'
Autor:
Nir Hacohen, Robert T Manguso, Russell W Jenkins, Moshe Sade-Feldman, Hongyan Xie, Aiping Jiang, Jonathan Perera
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/07f76434e50148cea32e82e38f0b4731
Autor:
William H. Tomaszewski, Jessica Waibl-Polania, Molly Chakraborty, Jonathan Perera, Jeremy Ratiu, Alexandra Miggelbrink, Donald P. McDonnell, Mustafa Khasraw, David M. Ashley, Peter E. Fecci, Luigi Racioppi, Luis Sanchez-Perez, Michael D. Gunn, John H. Sampson
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-17 (2022)
Responses to immune checkpoint blockade (ICB) in patients with glioblastoma are limited. Here the authors show that Calmodulin-Dependent Kinase Kinase 2 (CaMKK2) is expressed in tumor associated macrophages and neurons and is associated with resistan
Externí odkaz:
https://doaj.org/article/d2bad1bc29a045f7afdb7b2e7787b8de
Autor:
Robert Koucheki, Aaron Gazendam, Jonathan Perera, Anthony Griffin, Peter Ferguson, Jay Wunder, Kim Tsoi
Publikováno v:
European journal of orthopaedic surgerytraumatology : orthopedie traumatologie.
The treatment of giant cell tumors (GCT) of the distal radius remains challenging, with no consensus on the optimal surgical management. Surgical management remains the mainstay of treatment with options including intralesional curettage and en-bloc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4188b7c18afbf6ef50a9e9a0f27c750b
https://pubmed.ncbi.nlm.nih.gov/35377078
https://pubmed.ncbi.nlm.nih.gov/35377078
Autor:
Emily Lerner, Vincent D'Anniballe, William Tomaszewski, Jonathan Perera, Xiuyu Cui, Jessica Waibl-Polania, Daniel Wilkinson, Michael D. Gunn, Peter E. Fecci, Karolina Woroniecka
Publikováno v:
Cancer Research. 82:1378-1378
Major Histocompatibility Complex (MHC) Class I downregulation is a well described mechanism of tumor immune escape, posing a challenge for T cell based immunotherapies including immune checkpoint blockade (ICB). Recent studies, however, have demonstr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a58024a6fffb9e490540c94d2fd8e906
https://doi.org/10.1158/1538-7445.am2022-1378
https://doi.org/10.1158/1538-7445.am2022-1378
Autor:
Emily C Lerner, William Tomaszewski, Vincent D’Anniballe, Jonathan Perera, Xiuyu Cui, Daniel S Wilkinson, Jessica Waibl-Polania, Michael Gunn, Peter E Fecci, Karolina Woroniecka
Publikováno v:
The Journal of Immunology. 208:121.14-121.14
MHC-I downregulation is a well described mechanism of tumor immune escape. Thus, targeting tumors with low or no MHC-I expression remains a significant challenge for T cell-based immunotherapies, including immune checkpoint blockade (ICB). We previou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b470a12809aa18fd6ac9d921bfb1ca7d
https://doi.org/10.4049/jimmunol.208.supp.121.14
https://doi.org/10.4049/jimmunol.208.supp.121.14